2-硝基-4-甲氧基-5-甲基苯胺 | 55730-09-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-硝基-4-甲氧基-5-甲基苯胺
• 英文名称: 4-methoxy-5-methyl-2-nitroaniline
• CAS: 55730-09-1
• 化学式: C₈H₁₀N₂O₃
• 分子量: 182.179
• InChiKey: QRQYCJHQHGNOPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-硝基-4-甲氧基-5-甲基苯胺 在 盐酸 、 三氟乙酸 、 sodium nitrite 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 3-chloro-7-methoxy-6-methyl-1,2,4-benzotriazine 1-oxide
  参考文献：
  名称：

  Stille Coupling Reactions in the Synthesis of Hypoxia-Selective 3-Alkyl-1,2,4-Benzotriazine 1,4-Dioxide Anticancer Agents

  摘要：

  The introduction of a 3-alkyl substituent is a key step in the synthesis of 1,2,4-benzotriazine 1,4-dioxide hypoxia-selective anticancer agents, such as SN29751. The Stille reaction of 3-chloro-1,2,4-benzotriazine 1-oxides ( BTOs) 5 was inhibited by the presence of electron donating substituents on the benzo ring, thus limiting the range of compounds available for SAR studies. The use of 3-iodo-BTOs 8 did not provide a significant improvement in the yields of 3-ethyl-BTOs 6. Microwave-assisted Stille coupling of chlorides 5 gave dramatically improved yields, which were consistently superior to those from the corresponding iodides 8. The application of microwave-assisted synthesis extended the range of substituted BTOs available for SAR studies and provided an efficient, scalable synthesis of the investigational anticancer agent, SN29751 ( 1).

  DOI：

  10.1021/jo060986g
• 作为产物：
  描述：

  2-methyl-4-chloro-5-nitro-anisole 在 氨 、 水 作用下， 生成 2-硝基-4-甲氧基-5-甲基苯胺
  参考文献：
  名称：

  US2048790

  摘要：

  公开号：

文献信息

• Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
  申请人：Auckland Uniservices Limited

  公开号：EP1468688A2

  公开（公告）日：2004-10-20

  The present invention relates to a synergetistic composition comprising one or more benzoazine-mono-N-oxides, and one or more benzoazine 1,4 dioxides for use in cancer therapy. The invention also provides a range of novel 1,2,4 benzoazine-mono-N-oxides and related analogues. These can be used as potentiators of the cytotoxicity of existing anticancer drugs and therapies for cancer treatment.

  本发明涉及一种协同组合物，包括一种或多种苯并噁唑-单-N-氧化物，以及一种或多种苯并噁唑1,4-二氧化物，用于癌症治疗。 该发明还提供了一系列新颖的1,2,4苯并噁唑-单-N-氧化物及相关类似物。这些可以用作增强现有抗癌药物的细胞毒性和癌症治疗的治疗剂。
• 4, 5-Disubstituted primaquine analogs as potential antiprotozoan agents
  作者：Hanns Burghard、C.Dewitt Blanton

  DOI：10.1002/jps.2600690818

  日期：1980.8

  Significant blood schizonticidal activity was observed. The 5-fluoro-4-methylprimaquine analog also was active as a tissue schizonticidal agent when evaluated against P. cynomolgi in the rhesus monkey, as an antileishmanial agent when evaluated against Leishmania donovani in the hamster, and as a causal prophylactic agent when evaluated against P. berghei yoelii.

  合成了4，5-二甲基伯氨喹和5-氟-4-甲基伯氨喹，并在小鼠中针对伯氏疟原虫进行了评估。观察到明显的血液裂殖活动。当对猕猴中的食蟹猴进行评估时，5-氟-4-甲基伯氨喹类似物还可用作组织裂殖体杀虫剂，对仓鼠中的利什曼原虫进行评估时，该杀虫剂可以作为抗裂殖剂，对白鼠中的利什曼原虫进行评估时，可以用作因果预防剂。 P. berghei yoelii。
• Interconversion of benzofurazandione monoximes
  作者：A.S. Angeloni、D. Dal Monte、E. Sandri、G. Scapini

  DOI：10.1016/s0040-4020(01)97074-7

  日期：1974.1

  7-hydroxy-4-nitrosobenzofurazan as well as of their 6-chloro and methyl derivatives is described and the oxime structure of these compounds is established. NMR spectra of benzofurazan-4,5-dione-4-monoxime and benzofurazan-4,7-dione-4-monoxime show evidence for an interconversion, in solution, of two monoximes, the 4,5- and 4,7-derivative prevailing in organic solvents and aqueous alkaline media, respectively

  描述了5-羟基-4-亚硝基和7-羟基-4-亚硝基苯并呋喃的制备以及它们的6-氯和甲基衍生物，并确定了这些化合物的肟结构。苯并呋喃zan-4,5-二酮-4-一肟和苯并呋喃-4,7-二酮-4-一肟的NMR光谱显示了溶液中两种一元酚4,5-和4,7-衍生物相互转化的证据分别在有机溶剂和碱性水溶液中盛行。苯并呋喃-4,5-和4,7-二酮-4-一肟的氯和甲基衍生物在有机溶剂中显示出相似的相互转化。
• Benzimidazoles
  申请人：Edwards L. Michael

  公开号：US20060014756A1

  公开（公告）日：2006-01-19

  The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

  本发明涉及一般式（Ix）的生理活性化合物及含有这种化合物的组合物，以及它们的前药、药学上可接受的盐和溶剂化物，还涉及在式（Ix）范围内的新化合物和它们的制备方法。这种化合物和组合物具有有价值的药物性质，特别是抑制激酶的能力。
• Structure−Activity Relationships for 5-Substituted 1-Phenylbenzimidazoles as Selective Inhibitors of the Platelet-Derived Growth Factor Receptor
  作者：Brian D. Palmer、Alan J. Kraker、Brian G. Hartl、Athanasia D. Panopoulos、Robert L. Panek、Brian L. Batley、Gina H. Lu、Susanne Trumpp-Kallmeyer、H. D. Hollis Showalter、William A. Denny

  DOI：10.1021/jm980658b

  日期：1999.7.1

  Following an earlier discovery of 1-phenylbenzimidazoles as ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR), further structure-activity relationships for analogues (particularly 5-substituted derivatives) are reported. The data are consistent with a binding model (constructed from the homology-modeled structure of the catalytic subunit of the PDGFR using protein kinase A as the template) in which the ligand binds in the relatively narrow ATP site, with the phenyl ring pointing toward the interior of the pocket and the 5-position of the benzimidazole ring toward the mouth of the pocket. The narrow binding pocket allows a maximum torsion angle between the phenyl and benzimidazole rings of about 40 degrees, consistent with that calculated (43.6 degrees) for the minimum-energy conformation of the unsubstituted free ligand. The inactivity of 7- or 2'-substituted analogues is consistent with the greater torsion angle (and thus larger ligand cross-section) of such substituted analogues. There is substantial bulk tolerance for 5-substituents, which protrude out of the mouth of the hydrophobic pocket, with the most effective analogues being those bearing weak bases. On the basis of this model, 5-OR derivatives bearing cationic side chains were prepared as soluble analogues, and these showed sub-micromolar potencies against the isolated PDGFR enzyme. They were also moderately effective inhibitors of autophosphorylation of PDGFR in rat aortic vascular smooth muscle cells, with IC(50)s in the range 0.1-1 mu 1M.